Risks and benefits of antiretroviral therapy in HIV–HCV co-infected patients
Open Access
- 31 March 2005
- journal article
- editorial
- Published by Elsevier in Journal of Hepatology
- Vol. 42 (3) , 290-292
- https://doi.org/10.1016/j.jhep.2004.12.011
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART eraJournal of Hepatology, 2005
- Hepatocellular carcinoma in HIV-infected patientsAIDS, 2004
- Survival in patients with HIV infection and viral hepatitis B or CAIDS, 2004
- Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfectionThe Lancet, 2003
- Hospitalization Rates Differ by Hepatitis C Status in an Urban HIV CohortJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)AIDS, 2003
- The Impact of Hepatitis C Virus Coinfection on HIV Progression Before and After Highly Active Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Increasing Impact of Chronic Viral Hepatitis on Hospital Admissions and Mortality among HIV-Infected PatientsAIDS Research and Human Retroviruses, 2001
- Mortality among Human Immunodeficiency Virus-Infected Patients with Cirrhosis or Hepatocellular Carcinoma Due to Hepatitis C Virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997Clinical Infectious Diseases, 2001
- Increasing Mortality Due to End-Stage Liver Disease in Patients with Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 2001